Selected research
Market Structure
Global Soluble Guanylate Cyclase Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Soluble Guanylate Cyclase market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Soluble Guanylate Cyclase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Soluble Guanylate Cyclase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Soluble Guanylate Cyclase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Soluble Guanylate Cyclase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Soluble Guanylate Cyclase include Bayer AG, Topadur Pharma AG, SynZyme Technologies LLC, NicOx SA, Ironwood Pharmaceuticals Inc and Boehringer Ingelheim GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Soluble Guanylate Cyclase market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Soluble Guanylate Cyclase and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Soluble Guanylate Cyclase sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Soluble Guanylate Cyclase market size, projected growth trends, production technologies, key applications, and end-use industries.
Soluble Guanylate Cyclase Segment by Company
Bayer AG
Topadur Pharma AG
SynZyme Technologies LLC
NicOx SA
Ironwood Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Soluble Guanylate Cyclase Segment by Type
Hydroxyurea
IW-1701
BI-703704
BAY-1636183
Others
Soluble Guanylate Cyclase Segment by Application
Ophthalmology
Cardiovascular
Gastrointestinal
Metabolic Disorders
Others
Soluble Guanylate Cyclase Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Soluble Guanylate Cyclase market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Soluble Guanylate Cyclase and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Soluble Guanylate Cyclase.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Soluble Guanylate Cyclase market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Soluble Guanylate Cyclase manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Soluble Guanylate Cyclase in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Soluble Guanylate Cyclase in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Hydroxyurea
- IW-1701
- BI-703704
- BAY-1636183
- Others
Applications
- Ophthalmology
- Cardiovascular
- Gastrointestinal
- Metabolic Disorders
- Others
Companies covered
- Bayer AG
- Topadur Pharma AG
- SynZyme Technologies LLC
- NicOx SA
- Ironwood Pharmaceuticals Inc
- Boehringer Ingelheim GmbH
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Soluble Guanylate Cyclase Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Soluble Guanylate Cyclase Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Soluble Guanylate Cyclase Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Soluble Guanylate Cyclase Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Soluble Guanylate Cyclase Market Dynamics
- 2.1 Soluble Guanylate Cyclase Industry Trends
- 2.2 Soluble Guanylate Cyclase Industry Drivers
- 2.3 Soluble Guanylate Cyclase Industry Opportunities and Challenges
- 2.4 Soluble Guanylate Cyclase Industry Restraints
3 Soluble Guanylate Cyclase Market by Manufacturers
- 3.1 Global Soluble Guanylate Cyclase Revenue by Manufacturers (2021-2026)
- 3.2 Global Soluble Guanylate Cyclase Sales by Manufacturers (2021-2026)
- 3.3 Global Soluble Guanylate Cyclase Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Soluble Guanylate Cyclase Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Soluble Guanylate Cyclase Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Soluble Guanylate Cyclase Manufacturers, Product Type & Application
- 3.7 Global Soluble Guanylate Cyclase Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Soluble Guanylate Cyclase Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Soluble Guanylate Cyclase Players Market Share by Revenue in 2025
- 3.8.3 2025 Soluble Guanylate Cyclase Tier 1, Tier 2, and Tier 3
4 Soluble Guanylate Cyclase Market by Type
- 4.1 Soluble Guanylate Cyclase Type Introduction
- 4.1.1 Hydroxyurea
- 4.1.2 IW-1701
- 4.1.3 BI-703704
- 4.1.4 BAY-1636183
- 4.1.5 Others
- 4.2 Global Soluble Guanylate Cyclase Sales by Type
- 4.2.1 Global Soluble Guanylate Cyclase Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Soluble Guanylate Cyclase Sales by Type (2021-2032)
- 4.2.3 Global Soluble Guanylate Cyclase Sales Market Share by Type (2021-2032)
- 4.3 Global Soluble Guanylate Cyclase Revenue by Type
- 4.3.1 Global Soluble Guanylate Cyclase Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Soluble Guanylate Cyclase Revenue by Type (2021-2032)
- 4.3.3 Global Soluble Guanylate Cyclase Revenue Market Share by Type (2021-2032)
5 Soluble Guanylate Cyclase Market by Application
- 5.1 Soluble Guanylate Cyclase Application Introduction
- 5.1.1 Ophthalmology
- 5.1.2 Cardiovascular
- 5.1.3 Gastrointestinal
- 5.1.4 Metabolic Disorders
- 5.1.5 Others
- 5.2 Global Soluble Guanylate Cyclase Sales by Application
- 5.2.1 Global Soluble Guanylate Cyclase Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Soluble Guanylate Cyclase Sales by Application (2021-2032)
- 5.2.3 Global Soluble Guanylate Cyclase Sales Market Share by Application (2021-2032)
- 5.3 Global Soluble Guanylate Cyclase Revenue by Application
- 5.3.1 Global Soluble Guanylate Cyclase Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Soluble Guanylate Cyclase Revenue by Application (2021-2032)
- 5.3.3 Global Soluble Guanylate Cyclase Revenue Market Share by Application (2021-2032)
6 Global Soluble Guanylate Cyclase Sales by Region
- 6.1 Global Soluble Guanylate Cyclase Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Soluble Guanylate Cyclase Sales by Region (2021-2032)
- 6.2.1 Global Soluble Guanylate Cyclase Sales by Region (2021-2026)
- 6.2.2 Global Soluble Guanylate Cyclase Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Soluble Guanylate Cyclase Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Soluble Guanylate Cyclase Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Soluble Guanylate Cyclase Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Soluble Guanylate Cyclase Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Soluble Guanylate Cyclase Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Soluble Guanylate Cyclase Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Soluble Guanylate Cyclase Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Soluble Guanylate Cyclase Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Soluble Guanylate Cyclase Revenue by Region
- 7.1 Global Soluble Guanylate Cyclase Revenue by Region
- 7.1.1 Global Soluble Guanylate Cyclase Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Soluble Guanylate Cyclase Revenue by Region (2021-2026)
- 7.1.3 Global Soluble Guanylate Cyclase Revenue by Region (2027-2032)
- 7.1.4 Global Soluble Guanylate Cyclase Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Soluble Guanylate Cyclase Revenue (2021-2032)
- 7.2.2 North America Soluble Guanylate Cyclase Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Soluble Guanylate Cyclase Revenue (2021-2032)
- 7.3.2 Europe Soluble Guanylate Cyclase Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Soluble Guanylate Cyclase Revenue (2021-2032)
- 7.4.2 Asia-Pacific Soluble Guanylate Cyclase Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Soluble Guanylate Cyclase Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Soluble Guanylate Cyclase Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Bayer AG
- 8.1.1 Bayer AG Company Information
- 8.1.2 Bayer AG Business Overview
- 8.1.3 Bayer AG Soluble Guanylate Cyclase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Bayer AG Soluble Guanylate Cyclase Product Portfolio
- 8.1.5 Bayer AG Recent Developments
- 8.2 Topadur Pharma AG
- 8.2.1 Topadur Pharma AG Company Information
- 8.2.2 Topadur Pharma AG Business Overview
- 8.2.3 Topadur Pharma AG Soluble Guanylate Cyclase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Topadur Pharma AG Soluble Guanylate Cyclase Product Portfolio
- 8.2.5 Topadur Pharma AG Recent Developments
- 8.3 SynZyme Technologies LLC
- 8.3.1 SynZyme Technologies LLC Company Information
- 8.3.2 SynZyme Technologies LLC Business Overview
- 8.3.3 SynZyme Technologies LLC Soluble Guanylate Cyclase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 SynZyme Technologies LLC Soluble Guanylate Cyclase Product Portfolio
- 8.3.5 SynZyme Technologies LLC Recent Developments
- 8.4 NicOx SA
- 8.4.1 NicOx SA Company Information
- 8.4.2 NicOx SA Business Overview
- 8.4.3 NicOx SA Soluble Guanylate Cyclase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 NicOx SA Soluble Guanylate Cyclase Product Portfolio
- 8.4.5 NicOx SA Recent Developments
- 8.5 Ironwood Pharmaceuticals Inc
- 8.5.1 Ironwood Pharmaceuticals Inc Company Information
- 8.5.2 Ironwood Pharmaceuticals Inc Business Overview
- 8.5.3 Ironwood Pharmaceuticals Inc Soluble Guanylate Cyclase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Ironwood Pharmaceuticals Inc Soluble Guanylate Cyclase Product Portfolio
- 8.5.5 Ironwood Pharmaceuticals Inc Recent Developments
- 8.6 Boehringer Ingelheim GmbH
- 8.6.1 Boehringer Ingelheim GmbH Company Information
- 8.6.2 Boehringer Ingelheim GmbH Business Overview
- 8.6.3 Boehringer Ingelheim GmbH Soluble Guanylate Cyclase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Boehringer Ingelheim GmbH Soluble Guanylate Cyclase Product Portfolio
- 8.6.5 Boehringer Ingelheim GmbH Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Soluble Guanylate Cyclase Value Chain Analysis
- 9.1.1 Soluble Guanylate Cyclase Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Soluble Guanylate Cyclase Production Mode & Process
- 9.2 Soluble Guanylate Cyclase Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Soluble Guanylate Cyclase Distributors
- 9.2.3 Soluble Guanylate Cyclase Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst